Creso Pharma Limited
COPHF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $7,984 | $50,268 | $46,263 |
| - Cash | $1 | $1 | $7 | $6 |
| + Debt | $10 | $7 | $0 | $3 |
| Enterprise Value | $9 | $7,990 | $50,261 | $46,260 |
| Revenue | $19 | $9 | $6 | $2 |
| % Growth | 117.8% | 39.7% | 154% | – |
| Gross Profit | $2 | $0 | -$0 | -$4 |
| % Margin | 12.3% | 3.3% | -6.4% | -158.6% |
| EBITDA | -$25 | -$18 | -$28 | -$16 |
| % Margin | -133% | -202.8% | -451.2% | -673.5% |
| Net Income | -$52 | -$33 | -$32 | -$38 |
| % Margin | -277.2% | -377.3% | -510.8% | -1,535.2% |
| EPS Diluted | 0 | -0.022 | -0.029 | -0.1 |
| % Growth | 100% | 22% | 71.3% | – |
| Operating Cash Flow | $0 | -$31 | -$22 | -$10 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$8 | -$31 | -$23 | -$10 |